E-QURE CORP. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-05-21: Form 8-K; Period of report 2020-01-06; Description 8.01 Other Events; Details 8.01.
- 2020-01-21: Form 8-K; Period of report 2020-01-06; Description 8.01 Other Events; Details 8.01.
- 2018-10-18: Form 8-K; Period of report 2018-10-18; Description 8.01 Other Events; Details 8.01.
- 2018-07-30: Form 8-K; Period of report 2018-07-25; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-05-21 | 8-K | 2020-01-06 | 8.01 Other Events | 8.01 On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order (Release No. 34-88318) under Section 36 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. | form8-k.htm |
| 2020-01-21 | 8-K | 2020-01-06 | 8.01 Other Events | 8.01 E-Qure Corp., a Delaware corporation, OTCQB: EQUR (the “Company”), a medical device Company, reported today the following material updates regarding Bioelectrical Signal Therapy device (“BST Device) developed for the treatment of wounds via electrical stimulation, which is believed to result in accelerated wound healing by imitating the natural electrical current that occurs in injured skin on the human body. | form8-k.htm |
| 2018-10-18 | 8-K | 2018-10-18 | 8.01 Other Events | 8.01 E-Qure Corp., a Delaware corporation (the “Company”), reported today that it has successfully completed its 2018 funding program in the total amount of $1.231 Million (the “2018 Funding Program”). | form8-k.htm |
| 2018-07-30 | 8-K | 2018-07-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective July 25, 2018, E-Qure Corp. (the “Registrant”) announced the appointment of Mr. Ohad Goren, its Chief Executive Officer since June 2014, and Mr. Itsik Ben-Yesha, its Chief Technology Officer since June 2014, as members of the Registrant’s Board of Directors, joining Mr. Ron Weissberg and Dr. Michael Sessler on the Registrant’s Board. | form8-k.htm |
| 2017-02-22 | 8-K | 2017-02-21 | 8.01 Other Events | 8.01 On February 20, 2017, E-Qure Corp. (the "Registrant") received the official certification from the Israeli Ministry of Health authorizing the use of the Registrant's BST Device in Israel. | equr8k02222017.htm |
| 2017-02-21 | 8-K | 2017-02-21 | 8.01 Other Events | 8.01 On November 11, 2016, E-Qure Corp., a Delaware corporation (the "Registrant"), reported on Form 8-K that on October 14, 2016, the Registrant received notification from FDA that it had been granted conditional approval to the IDE application, authorizing the Registrant to commence a clinical investigation of our BST Device with 10 patients at a single site. | equr8k02212017.htm |
| 2017-02-13 | 8-K | 2017-02-13 | 8.01 Other Events | 8.01 On February 1, 2017, E-Qure Corp., OTCQB: EQUR (the "Registrant") was informed by its chairman and principal shareholder, Mr. Ron Weissberg, that because of his belief that the Registrant's shares of common stock, par value $0.0001 (the "Shares") were undervalued, he intends to purchase Shares in the open market and/or in privately negotiated transactions from persons other than the Registrant, having an aggregate market value of up to $100,000, at price up to $0.20 per Share. | equr8k02132017.htm |
| 2017-01-25 | 8-K | 2017-01-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | equre01252017.htm |
| 2016-11-01 | 8-K | 2016-11-01 | 8.01 Other Events | 8.01 On October 14, 2016, the Registrant received notification from FDA that it has granted conditional approval to the IDE application, authorizing us to commence a clinical investigation of our BST Device for wound healing. | equr8k_11022016.htm |
| 2016-07-25 | 8-K | 2016-07-18 | 8.01 Other Events | 8.01 On July 18, 2016, E-Qure Corp., a Delaware corporation (the "Registrant"), through its wholly-owned Israeli subsidiary, Esqure Advanced Medical Devices Ltd (the "Subsidiary"), received: (i) the CE Certificate of Conformity, attached hereto as Exhibit 99.1; and (ii) the ISO 13485 Certification, attached hereto as Exhibit 99.2. | 8k.htm |
| 2015-12-28 | 8-K | 2015-12-28 | 8.01 Other Events | 8.01 On June 6, 2014, E-Qure Corp., a Delaware corporation (the "Registrant") entered into an agreement (the Agreement") with Austen Biolnnovation Institute in Akron, Ohio ("ABIA"), a copy of which was attached as exhibit 10.8 to the Registration's Form S-1 filed with the SEC on September 5, 2014. | eure8k12282015.htm |
| 2015-10-27 | 8-K/A | 2015-10-27 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 The Registrant, E-Qure Corp., is filing this Form 8-K/A to include disclosure required by Item 2.01(f) that was not included in the Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 13, 2015. | equr8k10272015.htm |
| 2015-10-27 | 8-K/A | 2015-10-27 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 The Registrant, Emerald Medical Applications Corp. f/k/a Zaxis International Inc., is filing this Form 8-K/A to include disclosure required by Item 2.01(f) that was not included in the Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 13, 2015. | equr8k10272015.htm |
| 2015-10-13 | 8-K | 2015-10-13 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.06 Change in Shell Company Status; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.01 On September 29, 2014, the Registrant, through its wholly-owned Israeli subsidiary, Esqure Advanced Medical Devices Ltd., completed the acquisition of the remaining Lifewave assets under an Asset Purchase Agreement with Michael Cohen, a resident of the State of Israel and the control person of Lifewave (the "Seller"). 5.06 The Registrant is filing this Form 8-K to report that effective during the three-month period ended September 30, 2015, for the forgoing reasons and the completion of a series of transactions, agreements, ongoing operations and events described more fully in Items 1.01, 2.01 and 8.01, that have had the effect of causing the Registrant to cease being a shell company, as defined in Rule 12b-2 promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934, it is the Registrant's position that it is no longer a "shell" company. 8.01 The Registrant, a medical device company engaged in the business of commercializing its proprietary BST Device ™, is presently seeking an Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (the "FDA"), a prerequisite for commencing clinical trials under FDA regulations and being able to market the BST Device ™ in the United States. | equr8k.htm |
| 2015-08-03 | 8-K/A | 2015-08-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | equr8k_a.htm |
| 2015-07-30 | 8-K | 2015-07-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | equr8k07302015.htm |
| 2015-06-10 | 8-K | 2015-06-09 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 Effective July 1, 2015, E-Qure Corp., a Delaware corporation (the "Registrant"), has granted options under its 2015 Employee Incentive Plan to Professor Avi Ohry and Dr. Ben Zion Weiner (the "Advisors") for serving on the Scientific Advisory Board, established on January 1, 2015. 8.01 E-Qure Corp., a Delaware corporation (the "Registrant"), established a Scientific Advisory Board, effective January 1, 2015, appointing as its initial members, Professor Avi Ohry and Dr. Ben Zion Weiner, both residents of the State of Israel. | ecur8k06092015.htm |
| 2015-01-27 | 8-K/A | 2015-01-27 | 3.02 Unregistered Sales of Equity Securities | 3.02 The disclosure in this Form 8-K/A corrects the names of the subscribers contained in the Registrant's Form 8-K filed on January 21, 2015. | equr8k01272015.htm |
| 2015-01-21 | 8-K | 2015-01-20 | 3.02 Unregistered Sales of Equity Securities | 3.02 In December 2014, the Registrant issued restricted shares of common stock, par value $0.00001 per share (the "Shares") to three accredited investors set forth below at a subscription price of $0.50 per Share. | ecur8k_01202015.htm |
| 2014-10-10 | 8-K | 2014-10-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | equr_8k10102014.htm |
| 2014-08-22 | 8-K | 2014-08-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 20, 2014, the Registrant's Board of Directors accepted the resignation of Yoseph Zekri as secretary and a director of the Registrant. | adbi8k08222014.htm |
| 2014-08-12 | 8-K | 2014-08-12 | 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.02 During the period from February 2014 through April 2014, the Registrant issued convertible notes to the accredited investors set forth below. 5.03 Effective August 4, 2014, ADB International Group, Inc., a New Jersey corporation, completed a migratory merger with and into its wholly-owned subsidiary, ADB International Group, Inc., a Delaware corporation (the "Registrant") pursuant to an Agreement and Plan of Merger dated May 12, 2014 which was authorized by the Joint Consent of the Board of Directors and Majority Stockholders of the New Jersey corporation on May 12, 2014. | adbi8k08122014.htm |
| 2014-07-01 | 8-K | 2014-06-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | adbi06302014.htm |
| 2014-06-09 | 8-K | 2014-06-09 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 3.02 During the period from February through May, 2014, the Registrant accepted subscriptions from 41 accredited investors for 6,500,000 restricted shares of common stock resulting in total subscription proceeds of $2,600,000 at a price of $.40 per share. 5.02 On June 5, 2014, in connection with the Registrant's closing of the above-referenced Patent Purchase Agreement, the Registrant's board of directors appointed Mr. Ohad Goren as the Registrant's new Chief Executive Officer and Mr. Itsik Ben Yesha as the Registrant's Chief Technology Officer. | adbi8k_06092014.htm |
| 2014-06-06 | 8-K | 2014-06-05 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | adbi06062014.htm |
| 2014-05-29 | 8-K | 2014-05-28 | 3.02 Unregistered Sales of Equity Securities | 3.02 On May 20, 2014, the Registrant's CEO/CFO, Mr. Ron Weissberg, completed negotiations with 8 holders of promissory notes in the aggregate amount of $136,175 (the "Notes"), pursuant to which the Notes were deemed satisfied in full, in consideration for the payment by the Registrant of cash and/or the agreement to issue of shares of common stock as set forth in the table below. | adbi_8k05292014.htm |
| 2014-05-29 | 8-K | 2014-05-28 | 3.02 Unregistered Sales of Equity Securities | 3.02 During the periods set forth in the table below, Dynamic Applications Corp. (the "Registrant") issued and/or sold restricted shares of its common stock to named individuals and entities. | dyap8k_05282014.htm |
| 2013-12-27 | 8-K | 2013-12-27 | 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 3.02 On December 23, 2013, Mr. Ron Weissberg invested a total of $91,545 in the Registrant, evidenced by the purchase of 200,000,000 shares at par value per share and $71,545 evidenced by a convertible promissory note due December 31, 2014 (the "Convertible Note"). 5.02 On December 24, 2013, in connection with the above-referenced investment, the Registrant's board of directors appointed Ron Weissberg as its Chairman, Chief Executive Officer and Chief Financial Officer. | adbi_8k.htm |
| 2013-12-09 | 8-K/A | 2013-04-09 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 Effective January 30, 2013, ADB International Group, Inc. (“ADBI” or the “Company”) received notice that its auditor Michael F. Cronin, CPA ("MFC") resigned. | adbi8k.htm |
| 2013-04-09 | 8-K | 2013-04-09 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 Effective January 30, 2013, ADB International Group, Inc. (“ADBI” or the “Company”) received notice that its auditor Michael F. Cronin, CPA ("MFC") resigned. | adbi8k.htm |
| 2013-03-26 | 8-K | 2013-03-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 17, 2013, Mr. Shahar Ginsberg was appointed to be the Registrant's CEO, acting CFO and a director. | adbi8k.htm |